In 2017, Maryland enacted “An Act concerning Public Health – Essential Off-Patent or Generic Drugs – Price Gouging – Prohibition.” The Act, Md. Code, Health–General 2-802(a), prohibits manufacturers or wholesale distributors from “engag[ing] in price gouging in the sale of an essential off-patent or generic drug,” defines “price gouging” as “an unconscionable increase in the price of a prescription drug,” and “unconscionable increase” as “excessive and not justified by the cost of producing the drug or the cost of appropriate expansion of access to the drug to promote public health” that results in consumers having no meaningful choice about whether to purchase the drug at an excessive price due to the drug’s importance to their health and insufficient competition. The “essential” medications are “made available for sale in [Maryland]” and either appear on the Model List of Essential Medicines most recently adopted by the World Health Organization or are “designated . . . as an essential medicine due to [their] efficacy in treating a life-threatening health condition or a chronic health condition that substantially impairs an individual’s ability to engage in activities of daily living.” The Fourth Circuit reversed the dismissal of a “dormant commerce clause” challenge to the Act, finding that it directly regulates the price of transactions that occur outside Maryland. View "Association for Accessible Medicine v. Frosh" on Justia Law
Posted in: Antitrust & Trade Regulation, Commercial Law, Constitutional Law, Drugs & Biotech, Health Law
Dominion and Bransen entered into a contract wherein Bransen was paid $27 million for coal product which would satisfy rigid specifications and environmental regulations. When Bransen failed to deliver product meeting the requirements, Dominion filed suit in district court. Dominion was awarded partial summary judgment on claims related to Bransen's delivery of coke breeze, and the district court held in favor of Dominion after a bench trial on its claims related to the delivery of waste coal. The district court awarded Dominion $22 million in damages. The court affirmed the district court's ruling in favor of Dominion as to liability where Bransen was liable for delivery product that did not satisfy the contracts between the parties. The court rejected Bransen's argument that the district court awarded damages, including indirect damages, in violation of Section 8.8 of the parties' contract, and rejected Bransen's challenges to the calculation of the damages award. Because the court found no error, the court affirmed the district court's judgment. View "Virginia Electric and Power v. Bransen Energy" on Justia Law
Plaintiff filed a quiet title claim against Bank of New York ("BNY") after he failed to make payments on a loan for over a half of a year and BNY foreclosed on his property. At issue was whether BNY lacked authority to carry out the sale where plaintiff alleged that America's Wholesale Lender, the original lender, had authority to foreclose on the property. The court held that plaintiff's note plainly constituted a negotiable instrument under Va. Code. Ann. 8.3A-104 and that note was endorsed in blank. Therefore, BNY possessed the note at the time it attempted to foreclose on the property and once plaintiff defaulted on the property, Virgina law straightforwardly allowed BNY to take the actions that it did.